Asset Details
Do you wish to reserve the book?
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Do you wish to request the book?
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
2013
Overview
In this placebo-controlled trial, the γ-secretase inhibitor semagacestat did not improve cognitive status in patients with Alzheimer's disease and was associated with more adverse events than placebo, including skin cancers and infections.
Alzheimer's disease begins decades before the appearance of clinical symptoms, with the deposition of aggregated amyloid-beta (Aβ) peptide plaques in the cortex and hippocampus. This protein is cleaved from the amyloid precursor protein (APP) by the sequential action of β- and γ-secretases, producing fragments that include Aβ1-40 and Aβ1-42. Since the accumulation of aggregated Aβ is associated with disease progression, both β-secretase and γ-secretase represent potential therapeutic targets. Multiple small molecules can inhibit γ-secretase in vitro,
1
–
4
but Notch and other transmembrane proteins are also substrates for γ-secretase,
1
–
4
and studies have raised concern that the inhibition of γ-secretase could . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult and adolescent clinical studies
/ Aged
/ Alanine - analogs & derivatives
/ Alzheimer Disease - drug therapy
/ Amyloid beta-Peptides - blood
/ Amyloid Precursor Protein Secretases - antagonists & inhibitors
/ Biological and medical sciences
/ Cortex
/ Female
/ Humans
/ Male
/ Organic mental disorders. Neuropsychology
/ Patients
/ Plaques
/ Plasma
/ Psychology. Psychoanalysis. Psychiatry
/ Skin Neoplasms - chemically induced
/ Urine
